<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619865</url>
  </required_header>
  <id_info>
    <org_study_id>201110718</org_study_id>
    <secondary_id>114398</secondary_id>
    <nct_id>NCT01619865</nct_id>
  </id_info>
  <brief_title>Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors</brief_title>
  <acronym>GA-68</acronym>
  <official_title>Safety &amp; Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging &amp; Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sue O'Dorisio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging,&#xD;
      and measurement of response to treatment in patients with somatostatin receptor positive&#xD;
      tumors. Goals are to 1) compare this unique PET/CT scan with the current standard of care&#xD;
      which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high&#xD;
      resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in&#xD;
      diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those&#xD;
      patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as&#xD;
      anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used&#xD;
      to measure response to treatment. These studies will be obtained with the long term goal of&#xD;
      submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and&#xD;
      children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging,&#xD;
      and measurement of response to treatment in patients with somatostatin receptor positive&#xD;
      tumors. The goals are to 1) compare this unique PET/CT scan with the current standard of care&#xD;
      which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high&#xD;
      resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in&#xD;
      diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those&#xD;
      patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as&#xD;
      anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used&#xD;
      to measure response to treatment. These studies will be obtained with the long term goal of&#xD;
      submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and&#xD;
      children.&#xD;
&#xD;
      Project Design&#xD;
&#xD;
      68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of&#xD;
      Response to Treatment in Somatostatin Receptor Positive Tumors is a prospective, Phase 1-2,&#xD;
      single center, open-label study in subjects with known or suspected somatostatin receptor&#xD;
      positive tumor. Eligible participants will undergo baseline assessments at enrollment. Study&#xD;
      participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study with an option to&#xD;
      receive a second 68Ga-DOTATOC PET/CT if they begin a new treatment (surgery, hepatic&#xD;
      embolization, Sandostatin LAR, chemotherapy, targeted biological therapy, or peptide receptor&#xD;
      radiotherapy) within 30 days of the first scan. The second scan will be performed at a time&#xD;
      recommended by the treating physician as optimal interval to observe results from treatment.&#xD;
&#xD;
      Project Goal&#xD;
&#xD;
      This study is planned to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide&#xD;
      ([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of&#xD;
      response to treatment in patients with Somatostatin receptor expressing tumors.&#xD;
&#xD;
      Neuroendocrine tumors are solid malignant tumors that arise from dispersed neuroendocrine&#xD;
      cells found throughout the body. Gastroenteropancreatic neuroendocrine tumors (NETs) can be&#xD;
      divided into two groups: Carcinoid tumors that may arise from the lungs, stomach, small bowel&#xD;
      or colon and pancreatic neuroendocrine tumors (also known as pancreatic islet cell tumors).&#xD;
      The clinical behavior of NETs is extremely variable; some may cause hormone hypersecretion&#xD;
      and others may not, the majority of them are slow-growing tumors (well-differentiated NETs),&#xD;
      whereas some NETs are highly aggressive (poorly differentiated NETs). The incidence of NETs&#xD;
      is increasing, from 1.1/100,000 per year in 1973 to 5.3/100,000 per year in 20041. Among&#xD;
      NETs, 25% have distant metastases and 25% have regional involvement at the time of initial&#xD;
      diagnosis[1]. Other tumors that express high levels of somatostatin receptors include&#xD;
      neuroblastoma, medulloblastoma, and Ewing's sarcoma[2-4].&#xD;
&#xD;
      The radiological detection and staging of these tumors is challenging and requires a&#xD;
      multimodality approach. Somatostatin receptor imaging with In-111 Pentetreotide (OctreoScan)&#xD;
      and multiphase CT are the most commonly used modalities although the use of endoscopic&#xD;
      ultrasound and MRI is also increasing. Surgery is the only curative option for NETs. However,&#xD;
      curative surgery in malignant NET is possible in less than 30% of patients with recurrence&#xD;
      identified in the majority of patients as late as 15 years after initial surgery. Treatment&#xD;
      with somatostatin analogs, which include the short acting subcutaneous and long acting&#xD;
      release (LAR) octreotide, are effective in stabilizing NETs and have been recently&#xD;
      demonstrated to prolong the time to progression of disease[5]. Chemotherapy is generally not&#xD;
      effective in low grade NETs, but it may be helpful in high grade and pancreatic NETs. On the&#xD;
      other hand, neuroblastoma, medulloblastoma, and Ewing's sarcoma are initially responsive to&#xD;
      chemotherapy, but relapses are common and salvage therapies are not very effective, resulting&#xD;
      in &lt;30% overall survival at 5 years[6-8].&#xD;
&#xD;
      Somatostatin Receptor Targeted Imaging and Therapy&#xD;
&#xD;
      Tumors that express somatostatin receptors can be targeted with radiolabeled somatostatin&#xD;
      analogues for imaging and treatment. Somatostatin receptor gamma camera imaging with In-111&#xD;
      DTPA-octreotide (OctreoScan) targeting somatostatin receptor 2 (sstr2), is used routinely for&#xD;
      imaging of neuroendocrine tumors with a detection rate &gt;90% for well-differentiated carcinoid&#xD;
      tumors and majority of pancreatic NETs, but only a 50% detection rate for insulinomas, which&#xD;
      may show a weaker expression of sstr2[9].&#xD;
&#xD;
      Given the clinical efficacy of this radiolabeled peptide as a diagnostic agent, studies to&#xD;
      test if therapeutic radiation could be targeted to tumors in a similar manner was a logical&#xD;
      next step. Attempts to utilize In-111 DTPA Octreotide as a therapeutic agent have been&#xD;
      minimally effective due to short range of auger electrons utilized in this therapy. The&#xD;
      efficacy of this treatment was improved with the development of somatostatin analogues&#xD;
      labeled with beta emitting radioisotopes. Further studies have identified DOTA as a superior&#xD;
      chelator compared to DTPA, increasing the stability and receptor targeting of somatostatin&#xD;
      analogues[10]. There is now a large clinical experience with Yttrium-90 DOTA-tyr3-Octreotide&#xD;
      peptide radioreceptor therapy (PRRT) in Europe, primarily in adults with neuroendocrine&#xD;
      tumors[11]. An international Phase II clinical trial then followed and included several trial&#xD;
      sites in the United States, notably the University of Iowa, where we entered 40 subjects[12].&#xD;
      With its low toxicity profile, the significant improvement in symptoms and quality of life&#xD;
      and the lack of effective alternative therapies, PRRT has been suggested as possible&#xD;
      first-line therapy in adult patients with gastroenteropancreatic neuroendocrine tumor. Recent&#xD;
      data have also demonstrated a significant survival benefit with PRRT compared to historical&#xD;
      controls in this population. We have also now conducted a Phase I trial of&#xD;
      90Y-DOTA-tyr3-Octreotide in children and young adults at the University of Iowa, which also&#xD;
      shows promise of efficacy of this treatment in pediatric patient population[13]. We now&#xD;
      propose a new imaging agent for use in diagnosis and therapy of Somatostatin receptor&#xD;
      positive tumors.&#xD;
&#xD;
      Somatostatin Receptor PET Imaging with Ga-68 DOTA0-Tyr3-octreotide&#xD;
&#xD;
      More recently, positron emission tomography (PET) radiopharmaceuticals have been developed&#xD;
      that can be labeled with Gallium-68 (Ga-68). Gallium-68 is a generator product with a&#xD;
      half-life of 68 min (compared to 67 hours for In-111 in OctreoScan). The parent nuclide of&#xD;
      Ga-68 is Germanium-68, which has a half-life of 270.8 days. Ga-68 decays by 89% through&#xD;
      positron emission and 11% by electron capture. Its parent, A number of Ga-68 DOTA-conjugated&#xD;
      peptides have been introduced, including Ga-68 DOTA0-Tyr3]octreotide (Ga-68 DOTATOC), Ga-68&#xD;
      DOTA0-1NaI3-octreotide (Ga-68 DOTANOC) and [Ga-68 DOTA0-Tyr3]octreotate (Ga-68 DOTATOC). All&#xD;
      of these radiolabeled peptides bind to sstr2, although DOTANOC also binds to sstr 3 and sstr&#xD;
      5, and DOTATOC to sstr5[14]. The primary advantage of Ga-68 based somatostatin receptor PET&#xD;
      imaging over OctreoScan SPECT is the higher imaging resolution and accurate quantitation of&#xD;
      uptake due to robust attenuation correction. The improved resolution and quantitation of&#xD;
      uptake obtained with Ga-68 DOTATOC PET should provide a more accurate assessment of&#xD;
      somatostatin receptor density, which will lead to a more accurate prediction of treatment&#xD;
      response to somatostatin analogues. A recent study from Europe comparing Ga-68 DOTATOC with&#xD;
      Octreoscan found Ga-68 DOTATOC to be superior in detection of skeletal and pulmonary&#xD;
      involvement of neuroendocrine tumors[15].&#xD;
&#xD;
      Rationale and overall study design&#xD;
&#xD;
      Rationale:68Ga-DOTATOC positron emission tomography (PET) scanning and 90Y-DOTATOC peptide&#xD;
      receptor radionuclide therapy (PRRT) are readily available in Europe, but neither&#xD;
      radiopharmaceutical is approved for use in the United States. IND #61,907 is currently active&#xD;
      under the above named investigators for 90Y-DOTATOC PRRT in somatostatin receptor positive&#xD;
      tumors. These investigators have conducted a single institution Phase I trial of 90Y-DOTATOC&#xD;
      therapy in children and young adults (Appendix I) and have participated in a Phase II trial&#xD;
      of 90Y-DOTATOC PRRT in adults (also in Appendix II).&#xD;
&#xD;
      The purpose of this amendment to the IND application is to test the efficacy of&#xD;
      68Gallium-DOTATOC in diagnosis, staging, and determination of response to 90Y-DOTATOC PRRT in&#xD;
      children and adults with known or suspected somatostatin receptor positive tumors, including,&#xD;
      but not limited to neuroendocrine tumors, neuroblastoma, and medulloblastoma. 68Ga-DOTATOC&#xD;
      PET would replace 111In-DTPA-Octreotide single photon emission tomography (SPECT) imaging.&#xD;
      Whereas, Octreoscan uses a 222 MBq imaging dose of Indium (2.8 day half life) resulting in an&#xD;
      effective dose equivalent (HE) equal to 2.61 rads, [68Ga]DOTATOC (68 min half life) uses 185&#xD;
      MBq with an effective dose equivalent of 0.46 rads. In addition, [68Ga]DOTATOC PET/CT can be&#xD;
      completed within 2 hours compared to an Octreoscan which requires 3 visits over 24 hours,&#xD;
      making [68Ga]DOTATOC a much more convenient imaging choice for patients. The data obtained in&#xD;
      this Ga-68 DOTATOC PET study will be used to support the use of 68Ga-DOTATOC PET for&#xD;
      diagnosis and staging in patients with suspected or proven somatostatin receptor positive&#xD;
      tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2012</start_date>
  <completion_date type="Actual">August 27, 2017</completion_date>
  <primary_completion_date type="Actual">August 27, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The Octreoscan and 68Ga-DOTA-tyr3-Octreotide PET scans are read independently by two certified nuclear medicine physicians for discordant positive lesions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent</measure>
    <time_frame>During PET scan and 24 hours post scan</time_frame>
    <description>Subject receives an injection of 68Ga-DOTATOC, a somatostatin-like peptide that binds to somatostatin receptor and is tagged with a radionuclide that can be detected by positron emission tomography (PET). Whole body PET is performed; patient is queried regarding any adverse events immediately and again 24 hrs after completion of scan read by certified nuclear medicine physician to determine if any known tumor lesions take up 68Ga-DOTATOC.Severity of adverse events will be graded according to NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Adverse events are assessed immediately after PET scan and 24 hrs after completion of the scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events Related to the Use of the 68Ga-DOTATOC</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of subjects with adverse events related to the use of the 68Ga-DOTATOC radiopharmaceutical in accordance with National Cancer Institute (NCI) toxicity guidelines (NCI Common Terminology Criteria for Adverse Events version 4.0)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Carcinoid Tumors</condition>
  <condition>Neuroblastoma</condition>
  <condition>Medulloblastoma</condition>
  <arm_group>
    <arm_group_label>68Ga-DOTATOC PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-DOTATOC PET/CT</intervention_name>
    <description>1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.</description>
    <arm_group_label>68Ga-DOTATOC PET/CT</arm_group_label>
    <other_name>Gallium 68-DOTATOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age greater than or equal to 2 years&#xD;
&#xD;
          -  Known or suspected somatostatin receptor positive tumor such as carcinoid;&#xD;
             neuroendocrine tumor; neuroblastoma; medulloblastoma; pheochromocytoma. Supporting&#xD;
             evidence may include MRI, CT, biochemical markers, and or pathology report.&#xD;
&#xD;
          -  Karnofsky performance status or Lansky Play Scale status of greater than 50 (or&#xD;
             ECOG/WHO equivalent)&#xD;
&#xD;
          -  Subject is male; or is a female who is either pre-menarchal, surgically sterile (has&#xD;
             had a documented bilateral oophorectomy and/or documented hysterectomy),&#xD;
             postmenopausal (&gt; 1 years without menses), non-lactating, or of childbearing potential&#xD;
             for whom a serum pregnancy test (with the results known prior to investigational&#xD;
             product administration) is negative. A negative serum pregnancy test will be required&#xD;
             for all female subjects with child bearing potential. If a false pregnancy test is&#xD;
             suspected, e.g., perimenopausal condition, an obstetrician will be consulted to&#xD;
             determine if she is/is capable of becoming pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject weighs more than 400 pounds (Subjects who weigh more than 400 pounds will not&#xD;
             be able to fit inside the imaging machines).&#xD;
&#xD;
          -  Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,&#xD;
             etc.)&#xD;
&#xD;
          -  Inability to complete the needed investigational and standard-of-care imaging&#xD;
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)&#xD;
&#xD;
          -  Does the subject have any additional medical condition, serious intercurrent illness,&#xD;
             or other extenuating circumstance that, in the opinion of the Investigator, may&#xD;
             significantly interfere with study compliance?&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue O'Dorisio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Health Care</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Abongwa C, Mott S, Schafer B, McNeely P, Abusin G, O'Dorisio T, Zamba G, O'Dorisio MS, Menda Y. Safety and accuracy of (68)Ga-DOTATOC PET/CT in children and young adults with solid tumors. Am J Nucl Med Mol Imaging. 2017 Nov 1;7(5):228-235. eCollection 2017.</citation>
    <PMID>29181270</PMID>
  </results_reference>
  <results_reference>
    <citation>Menda Y, O'Dorisio TM, Howe JR, Schultz M, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS. Localization of Unknown Primary Site with (68)Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. J Nucl Med. 2017 Jul;58(7):1054-1057. doi: 10.2967/jnumed.116.180984. Epub 2017 Feb 2.</citation>
    <PMID>28153957</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <results_first_submitted>November 18, 2019</results_first_submitted>
  <results_first_submitted_qc>January 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>July 24, 2021</last_update_submitted>
  <last_update_submitted_qc>July 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Sue O'Dorisio</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>GA-68</keyword>
  <keyword>Gallium 68</keyword>
  <keyword>GA-68 PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edotreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD are entered into the subject's electronic medical record and are shared with referring physicians when obtained.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Results are shared when clinically available.</ipd_time_frame>
    <ipd_access_criteria>Results are placed in patient's electronic medical record.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT01619865/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the University of Iowa Holden Comprehensive Cancer Center Clinics and University of Iowa Children's Hospital. Participants being seen for known or suspected somatostatin receptor positive tumors were recruited for the study. Malignancies included neuroblastoma, medulloblastoma, and pheochromocytoma.</recruitment_details>
      <pre_assignment_details>Female subjects of childbearing potential were given a pregnancy test (serum) prior to receiving research-related radiation. A women who was pregnant could not participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>68Ga-DOTATOC PET/CT</title>
          <description>68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors&#xD;
68Ga-DOTATOC PET/C: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject not able to comply</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects with known neuroendocrine tumor with lesion identified on CT or MRI. Subjects with suspected neuroendocrine tumor with no lesion identified on CT or MRI.</population>
      <group_list>
        <group group_id="B1">
          <title>68Ga-DOTATOC PET/CT</title>
          <description>68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors&#xD;
68Ga-DOTATOC PET/C: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="223"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="3" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent</title>
        <description>Subject receives an injection of 68Ga-DOTATOC, a somatostatin-like peptide that binds to somatostatin receptor and is tagged with a radionuclide that can be detected by positron emission tomography (PET). Whole body PET is performed; patient is queried regarding any adverse events immediately and again 24 hrs after completion of scan read by certified nuclear medicine physician to determine if any known tumor lesions take up 68Ga-DOTATOC.Severity of adverse events will be graded according to NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Adverse events are assessed immediately after PET scan and 24 hrs after completion of the scan.</description>
        <time_frame>During PET scan and 24 hours post scan</time_frame>
        <population>Subjects who reported an adverse event and relationship of adverse event to study drug (68Ga-DOTATOC). Several subjects reported more than one adverse event; thus, the number of subjects who experienced an event will be less than the number of events.</population>
        <group_list>
          <group group_id="O1">
            <title>68Ga-DOTATOC PET/CT</title>
            <description>68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors&#xD;
68Ga-DOTATOC PET/C: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent</title>
          <description>Subject receives an injection of 68Ga-DOTATOC, a somatostatin-like peptide that binds to somatostatin receptor and is tagged with a radionuclide that can be detected by positron emission tomography (PET). Whole body PET is performed; patient is queried regarding any adverse events immediately and again 24 hrs after completion of scan read by certified nuclear medicine physician to determine if any known tumor lesions take up 68Ga-DOTATOC.Severity of adverse events will be graded according to NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Adverse events are assessed immediately after PET scan and 24 hrs after completion of the scan.</description>
          <population>Subjects who reported an adverse event and relationship of adverse event to study drug (68Ga-DOTATOC). Several subjects reported more than one adverse event; thus, the number of subjects who experienced an event will be less than the number of events.</population>
          <units>Adverse events reported</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probably related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlikely related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events Related to the Use of the 68Ga-DOTATOC</title>
        <description>Number of subjects with adverse events related to the use of the 68Ga-DOTATOC radiopharmaceutical in accordance with National Cancer Institute (NCI) toxicity guidelines (NCI Common Terminology Criteria for Adverse Events version 4.0)</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>68Ga-DOTATOC PET/CT</title>
            <description>68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors&#xD;
68Ga-DOTATOC PET/CT: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events Related to the Use of the 68Ga-DOTATOC</title>
          <description>Number of subjects with adverse events related to the use of the 68Ga-DOTATOC radiopharmaceutical in accordance with National Cancer Institute (NCI) toxicity guidelines (NCI Common Terminology Criteria for Adverse Events version 4.0)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of subjects with no adverse events (AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of subjects with Grade 1 or 2 AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of subjects with Grade 3 AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of subjects with Grade 4 or 5 AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of study drug injection, through PET scan up to 24 hours post injection.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>68Ga-DOTATOC PET/CT</title>
          <description>68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors&#xD;
68Ga-DOTATOC PET/C: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized of specific area (not due to neuropathy - Whole body/generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General - Other (Specify, __)</sub_title>
                <description>palpatations</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis (non-septic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) - Whole body/generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain - Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain-neck</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Neurology - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual/Reproductive Function - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Urticaria (hives, welts, wheals)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sue O'Dorisio, MD, PhD</name_or_title>
      <organization>University of Iowa Holden Comprehensive Cancer Center</organization>
      <phone>319-356-7873</phone>
      <email>sue-odorisio@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

